|Bid||1.1800 x 21500|
|Ask||1.2100 x 3200|
|Day's Range||1.1300 - 1.2100|
|52 Week Range||0.4510 - 2.2600|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
This version of the release contains a corrected hyperlink.RALEIGH, NC / ACCESSWIRE / May 19, 2021 / 9 Meters Biopharma, Inc.
RALEIGH, NC / ACCESSWIRE / May 18, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company focused on rare and unmet needs in gastroenterology, today announced that the Company's CEO, John Temperato will present a corporate update at Oppenheimer's Rare & Orphan Disease Summit and invites investors to participate via webcast and in one-on-one meetings.
RALEIGH, NC / ACCESSWIRE / May 17, 2021 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage biotechnology company focused on rare and unmet needs in gastroenterology, announced today that the United States Adopted Names (USAN) Council has officially designated the Company's long-acting injectable glucagon-like peptide-1 (GLP-1) receptor agonist drug candidate for short bowel syndrome, NM-002, as "vurolenatide.